文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-RGD PET/CT显像评估动静脉畸形血管生成的临床可行性研究

A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using 68Ga-RGD PET/CT.
PubMed 文献 · J Nucl Med · 2019-09-13

结果显示AVM病灶摄取均增高,病灶与血池、肌肉比值分别为3.5±2.2和4.6±2.8,提示68Ga-RGD PET/CT可用于定量评估AVM的血管生成。

要点

  • AVM病灶与血池、肌肉的摄取比值分别为3.5±2.2和4.6±2.8。
  • 免疫组化显示AVM内皮细胞表达整合素αvβ3,与RGD显像靶点一致。

核心结论

  • 68Ga-RGD PET/CT在具有血管生成活性的AVM中显示摄取增高,提示可用于定量评估AVM的血管生成。

研究设计与样本

  • 所有患者注射68Ga-RGD后60分钟行PET/CT显像(平均剂量207±5 MBq)。
  • 对AVM、血池和肌肉的摄取以SUVmax和SUVpeak进行定量,并对PET/CT图像作描述性分析。
  • 对周围型AVM手术活检切片行免疫组化分析,观察整合素αvβ3的表达模式。

主要发现

  • 68Ga-RGD PET/CT显示所有AVM病灶摄取增高(平均SUVmax 3.0±1.1,平均SUVpeak 2.2±0.9)。
  • 病灶与血池比值3.5±2.2,病灶与肌肉比值4.6±2.8。
  • AVM中血池和肌肉摄取均显著高于背景组织(分别为P=0.0006和P=0.0014)。
  • 初步观察发现多灶性AVM病灶摄取以及累及骨完整性病例的骨内成分摄取增高。
  • 免疫组化显示AVM内皮细胞胞质和胞膜表达整合素αvβ3。

关键数值与推荐

  • 显像时间点为注射68Ga-RGD后60分钟,平均注射剂量207±5 MBq。
  • 定量指标采用SUVmax和SUVpeak,并以病灶与血池、肌肉比值描述摄取。

临床怎么用

  • 68Ga-RGD PET/CT有望作为无创工具定量评估周围型AVM的血管生成状态。
  • 研究提示该显像未来可能用于指导治疗决策和评估抗血管生成治疗反应,但尚需进一步研究。

局限性

  • 原文指出需开展进一步研究探索该显像指导治疗决策和评估抗血管生成治疗反应的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Arteriovenous malformations (AVMs) have an inherent capacity to form new blood vessels, resulting in excessive lesion growth, and this process is further triggered by the release of angiogenic factors. 68Ga-labeled arginine-glycine-aspartate tripeptide sequence (RGD) PET/CT imaging may provide insight into the angiogenic status and treatment response of AVMs. This clinical feasibility study was performed to demonstrate that 68Ga-RGD PET/CT imaging can be used to quantitatively assess angiogenesis in peripheral AVMs. Methods: Ten patients with a peripheral AVM (mean age, 40 y; 4 men and 6 women) and scheduled for endovascular embolization treatment were prospectively included. All patients underwent 68Ga-RGD PET/CT imaging 60 min after injection (mean dose, 207 ± 5 MBq). Uptake in the AVM, blood pool, and muscle was quantified as SUVmax and SUVpeak, and a descriptive analysis of the PET/CT images was performed. Furthermore, immunohistochemical analysis was performed on surgical biopsy sections of peripheral AVMs to investigate the expression pattern of integrin αvβ3Results:68Ga-RGD PET/CT imaging showed enhanced uptake in all AVM lesions (mean SUVmax, 3.0 ± 1.1; mean SUVpeak, 2.2 ± 0.9). Lesion-to-blood and lesion-to-muscle ratios were 3.5 ± 2.2 and 4.6 ± 2.8, respectively. Uptake in blood and muscle was significantly higher in AVMs than in background tissue (P = 0.0006 and P = 0.0014, respectively). Initial observations included uptake in multifocal AVM lesions and enhanced uptake in intraosseous components in those AVM cases affecting bone integrity. Immunohistochemical analysis revealed cytoplasmatic and membranous integrin αvβ3 expression in the endothelial cells of AVMs. Conclusion: This feasibility study showed increased uptake in AVMs with angiogenic activity, compared with surrounding tissue without angiogenic activity, suggesting that 68Ga-RGD PET/CT imaging can be used as a tool to quantitatively determine angiogenesis in AVMs. Further studies will be conducted to explore the potential of 68Ga-RGD PET/CT imaging for guiding current treatment decisions and for assessing response to antiangiogenic treatment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lobeek D, Bouwman FCM, Aarntzen EHJG, et al. A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using 68Ga-RGD PET/CT. J Nucl Med. 2019. PMID: 31519800. doi:10.2967/jnumed.119.231167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。